- Home
- AIHS vs NXTC Comparison
AIHS vs NXTC Comparison
Compare AIHS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- NXTC
- Stock Information
- Founded
- AIHS 2014
- NXTC 2015
- Country
- AIHS China
- NXTC United States
- Employees
- AIHS N/A
- NXTC N/A
- Industry
- AIHS Finance: Consumer Services
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- AIHS Finance
- NXTC Health Care
- Exchange
- AIHS Nasdaq
- NXTC Nasdaq
- Market Cap
- AIHS 11.9M
- NXTC 13.9M
- IPO Year
- AIHS 2018
- NXTC 2019
- Fundamental
- Price
- AIHS $0.29
- NXTC $0.45
- Analyst Decision
- AIHS
- NXTC Strong Buy
- Analyst Count
- AIHS 0
- NXTC 2
- Target Price
- AIHS N/A
- NXTC $3.50
- AVG Volume (30 Days)
- AIHS 4.2M
- NXTC 346.6K
- Earning Date
- AIHS 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- AIHS N/A
- NXTC N/A
- EPS Growth
- AIHS N/A
- NXTC N/A
- EPS
- AIHS N/A
- NXTC N/A
- Revenue
- AIHS $5,878,700.00
- NXTC N/A
- Revenue This Year
- AIHS N/A
- NXTC N/A
- Revenue Next Year
- AIHS N/A
- NXTC N/A
- P/E Ratio
- AIHS N/A
- NXTC N/A
- Revenue Growth
- AIHS 12.21
- NXTC N/A
- 52 Week Low
- AIHS $0.26
- NXTC $0.22
- 52 Week High
- AIHS $1.70
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- AIHS 29.79
- NXTC 44.08
- Support Level
- AIHS $0.29
- NXTC $0.45
- Resistance Level
- AIHS $0.32
- NXTC $0.49
- Average True Range (ATR)
- AIHS 0.08
- NXTC 0.06
- MACD
- AIHS -0.03
- NXTC -0.01
- Stochastic Oscillator
- AIHS 2.60
- NXTC 0.74
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.